VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Has given written informed consent before any      │ Has given written informed consent before any      │     100 │
│ study-related activity is performed                │ study-related activity is performed                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Advanced hormone-dependent prostate cancer for     │ Advanced hormone-dependent prostate cancer for     │     100 │
│ which androgen deprivation therapy is indicated,   │ which androgen deprivation therapy is indicated,   │         │
│ and independently from this trial, Firmagon® is    │ and independently from this trial, Firmagon® is    │         │
│ intended to be used for treatment                  │ intended to be used for treatment                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Age greater than or equal to 18 years and less     │ Age greater than or equal to 18 years and less     │     100 │
│ than 80 years                                      │ than 80 years                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Advanced hormone-dependent prostate cancer without │ Advanced hormone-dependent prostate cancer without │     100 │
│ any other clinically significant disorder          │ any other clinically significant disorder          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Life expectancy of at least 12 months as per the   │ Life expectancy of at least 12 months as per the   │     100 │
│ investigator's judgement                           │ investigator's judgement                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Previous or concurrent hormonal management of      │ Previous or concurrent hormonal management of      │     100 │
│ prostate cancer                                    │ prostate cancer                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Contraindication for prescription of Firmagon®     │ Contraindication for prescription of Firmagon®     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Considered as a candidate for curative therapy     │ Considered as a candidate for curative therapy     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of severe untreated asthma, anaphylactic   │ History of severe untreated asthma, anaphylactic   │     100 │
│ reactions or severe urticaria and/or angioedema    │ reactions or severe urticaria and/or angioedema    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ QTc interval over 450 msec or risk factors for     │ QTc interval over 450 msec or risk factors for     │     100 │
│ torsades de pointes or on Class IA and Class III   │ torsades de pointes or on Class IA and Class III   │         │
│ anti arrhythmic medications                        │ anti arrhythmic medications                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Cancer within the last 5 years except prostate     │ Cancer within the last 5 years except prostate     │     100 │
│ cancer and surgically removed basal or squamous    │ cancer and surgically removed basal or squamous    │         │
│ cell carcinoma of the skin                         │ cell carcinoma of the skin                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known or suspected hepatic, symptomatic biliary    │ Known or suspected hepatic, symptomatic biliary    │     100 │
│ disease (this includes moderate to severe chronic  │ disease (this includes moderate to severe chronic  │         │
│ hepatic impairment)                                │ hepatic impairment)                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with clinically significant laboratory    │ Patients with clinically significant laboratory    │     100 │
│ abnormalities / disorders other than prostate      │ abnormalities / disorders other than prostate      │         │
│ cancer                                             │ cancer                                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient with Hepatitis B Virus (HBV), Hepatitis C  │ Patient with Hepatitis B Virus (HBV), Hepatitis C  │     100 │
│ Virus (HCV) and Human Immunodeficiency Virus (HIV) │ Virus (HCV) and Human Immunodeficiency Virus (HIV) │         │
│ infections                                         │ infections                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ PSA ≥ 2 ng/mL at screening                         │ PSA = 2 ng/mL at screening                         │      96 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Easten Cooperative Oncology Group score ≤ 2        │ Easten Cooperative Oncology Group score = 2        │      98 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Concurrent treatment with a 5-α-reductase          │ Concurrent treatment with a 5-a-reductase          │      98 │
│ inhibitor                                          │ inhibitor                                          │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤═══════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                                 │   Score │
╞═══════════════════════════════════╪═══════════════════════════════════════════════╪═════════╡
│ Must be MALE                      │ Easten Cooperative Oncology Group score = 2   │      18 │
├───────────────────────────────────┼───────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years │ Previous or concurrent hormonal management of │      40 │
│                                   │ prostate cancer                               │         │
├───────────────────────────────────┼───────────────────────────────────────────────┼─────────┤
│ Must have maximum age of 79 Years │ Previous or concurrent hormonal management of │      40 │
│                                   │ prostate cancer                               │         │
╘═══════════════════════════════════╧═══════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 97
Average Levenshtein Ratio of individual lines: 89.5
OverAll Ratio: 93.25
